Affordable Access

deepdyve-link
Publisher Website

Might dolutegravir be part of a functional cure for HIV?

Authors
  • Wainberg, Mark A1, 2, 3
  • Han, Ying-Shan1
  • Mesplède, Thibault1
  • 1 a McGill University AIDS Centre, Lady Davis for Medical Research, Jewish General Hospital, Montréal, Que., Canada.
  • 2 b Division of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Que., Canada.
  • 3 c Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, Que., Canada.
Type
Published Article
Journal
Canadian Journal of Microbiology
Publisher
Canadian Science Publishing
Publication Date
May 2016
Volume
62
Issue
5
Pages
375–382
Identifiers
DOI: 10.1139/cjm-2015-0725
PMID: 27031127
Source
Medline
Keywords
License
Unknown

Abstract

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.

Report this publication

Statistics

Seen <100 times